FDA flags potential VEGF-related safety concern in Summit rejection letter
The FDA flagged a safety issue in its review of Summit Therapeutics’ and Akeso's now-rejected cancer drug ivonescimab, raising questions about the viability of the whole class of new bispecifics, though the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.